Amphetamine Sulfate (Evekeo)
Slide 2: Introduction to Evekeo
Amphetamine sulfate Evekeo is a defined central stimulant (Martin & Le, 2023)
The immediate-release racemic mixture formulation is distinctive
Combines d-amphetamine and l-amphetamine, providing therapeutic activity
FDA-approved ADHD and narcolepsy treatment
Enhances attentional control, behavioral regulation, and performance
Presentation examines pharmacology, safety, and clinical application
Evekeo is an amphetamine sulfate prescription drug, a central nervous system stimulant,
primarily applied to treat attention deficit hyperactivity disorder and narcolepsy (Martin &
Le, 2023). Evekeo and the other stimulant drugs are the same, only that they are immediate-
Release medications with a unique 1:1 ratio of d-amphetamine and l-amphetamine. The
contribution made in this piece is both central and peripheral, and it enhances the increased
concentration and control of behavior. The given presentation will critically examine the
pharmacological properties, dosing dynamics, risks, and clinical application of Evekeo in the
advanced nursing practice. The information about its classification and its therapeutic role is
crucial in order to administer this drug safely and to choose the patients correctly. The
supporting knowledge provides nurses with the instruments to evaluate the effectiveness,
safety issues, and the suitability of a particular medication in dissimilar groups of patients. In this
Introduction, the learners would have a basic knowledge of how Evekeo would integrate into
The holistic plans of ADHD management.
Slide 3: Why Evekeo Is Unique
Unique racemic amphetamine composition distinguishes Evekeo
D isomer enhances focus in the central nervous system (Patel et al., 2025)
L isomer regulates the hyperactivity of peripheral stimulation
Immediate release permits precise symptom control
Flexible dosing improves individualized treatment planning
Benefits patients who are intolerant of extended-release stimulants
One of the unique features of Evekeo is the fact that it is a 1:1 racemic compound of d-
amphetamine and l-amphetamine, unlike most of the single-isomer stimulant drugs. The d-
The amphetamine molecule has more intense central nervous system stimulation, which enhances
focus, attention, and thinking (Patel et al., 2025). On the contrary, l-amphetamine adds
peripheral activity, which helps in managing motor hyperactivity and impulsivity. Such a
Dual action helps to manage more symptoms of ADHD patients. It also has an immediate-
A release formulation that enables clinicians to adjust the dosing depending on the daily
functional requirements. This is especially helpful among patients requiring special attention
to their symptoms at a limited time of the day, when they have to spend time at school or at
college. Evekeo offers a clinically beneficial option to those who are unable to tolerate the
side effects or even sleep with extended-release stimulants. All these features make Evekeo a
A very versatile therapy choice in the pharmacotherapy of ADHD in advanced stages.
Slide 4: Mechanism of Action
Promotes dopamine and norepinephrine presynaptic neuronal release
Blocks neurotransmitter reuptake, synaptic cleft prolongation (Martin & Le, 2023)
Enhances cortical signaling attention regulation pathways
Strengthens executive functioning and impulse control capacity
Modulates reward processing, motivational behavioral stability
Supports therapeutic synergy in psychosocial intervention planning
Evekeo works by encouraging the discharge of dopamine and norepinephrine by presynaptic
nerve endings as well as hindering their uptake by the synaptic cleft. The two factors further
elevate the concentration of these neurotransmitters, which promotes synaptic transmission
and cortical activation (Martin & Le, 2023). Dopamine is essential in attention, motivation,
and thinking, and norepinephrine is significant in alertness and impulse control. Evekeo
enhances executive functioning and decreases hyperactivity and impulsivity through the
action of increasing the availability of neurotransmitters. These pharmacodynamic actions
enable patients to maintain concentration, plan, and control their behavioral reactions better.
There is also an increased reward processing, which leads to a more positive adherence to
structured routines. This mechanism is critical to the knowledge of nurses since it is used to
guide monitoring practices, expect side effects, and to educate patients. This is the knowledge
that facilitates good clinical judgment and enhances evidence-based drug administration in
advanced nursing practice.
Slide 5: Dosing Guidelines
Pediatric initial dosing: five milligrams twice
Adult dosing is individualized based on symptom tolerance
Gradual titration ensures optimal therapeutic effect
Maximum dosage determined by clinical judgment for safety
Morning administration reduces the adverse effects of insomnia
Continuous monitoring adjusts dosage and clinical evaluation
The dosage of Evekeo is to be adhered to with ample care to the patient's age, the intensity of
the symptoms, and the response to treatment. In children between six and twelve years, the initial dose is typically five milligrams twice daily, with titration being performed after every
one week. Adult dosing is similarly given in an individualized way, with the focus on the
principles of minimum effective dose. Titration allows clinical practitioners to trade off
symptom control and overstimulation and negative symptoms. The maximum doses are
administered and determined depending on the patient's tolerance and clinical response, and
are tightly supervised by the cardiovascular team. It is to be administered in the morning to
reduce the risks of insomnia and sleeping disorders. Nurses may play a critical role in
enhancing compliance, identifying symptom changes, and educating patients on their lapses.
The follow-up is done frequently, and it not only ensures the proper dose adjustment but also
ensures the safety of therapeutic means. It is a dose-controlled program that advanced
positive clinical outcomes and eradicated overexposure to stimulants.
Slide 6: Major Interactions
MAO inhibitors cause hypertensive crisis accumulation
SSRIs and SNRIs increase serotonin syndrome risk (Simon et al., 2024)
Antihypertensives' interaction alters cardiovascular stability control
Alcohol potentiates central nervous system toxicity
Sympathomimetics elevate tachycardia and hypertension complications significantly
Close monitoring prevents pharmacodynamic adverse outcomes
Evekeo contains some significant drug interactions that may cause severe clinical effects.
Interactions with monoamine oxidase inhibitors lead to a large amount of norepinephrine
accumulation that can cause life-threatening hypertensive crises. Together with SSRIs or
SNRI, there is an increased risk of developing serotonin syndrome, which includes agitation,
hyperthermia, and neuromuscular abnormalities (Simon et al., 2024). Sympathomimetic
The effects of amphetamines could lead to a decrease in the efficacy of antihypertensive
medications, which change the control of blood pressure. Alcohol consumption also enhances the central nervous system stimulation and behavioral instability. Other
sympathomimetic agent drugs burden the heart and elevate the risk of tachycardia and
hypertension. To prevent such interactions, nurses are supposed to involve the patient
in complete medication reconciliation as well as patient education. The constant supervision
assists in detecting the adverse reactions at an early stage, as well as in the safe use of
pharmacological practice in the clinical setting.
Slide 7: Contraindications
Sympathomimetic effects worsen cardiovascular disease outcomes
Historically, substance abuse increases the potential for dependence.
Mydriasis elevates intraocular pressure, causing closure of the glaucoma
Anxiety disorders amplify stimulant psychiatric instability
Hyperthyroidism increases the risk of cardiovascular overstimulation risks
Psychotic disorders exacerbated stimulant-induced exacerbations
Use of Evekeo in patients with severe cardiovascular disease should be avoided due to its
sympathomimetic nature that raises the heart rate and blood pressure, predisposing to the
development of myocardial events. The patients with a substance abuse history are
particularly vulnerable to abuse and addiction, and alternative therapy is needed. Evekeo
produces mydriasis in a patient with angle-closure glaucoma, which is potentially dangerous
since it may increase the intraocular pressure. The hyperthyroid patients are also more
sensitive to the stimulants, and this increases the risk of severe cardiovascular reactions.
Psychiatric conditions such as psychosis and acute anxiety may worsen with central
stimulation. Nurses are expected to conduct a comprehensive inspection of the patients they
are going to administer to identify such risks. The knowledge of these contraindications is
one of the tools to guarantee the safe ways of prescribing the medications and prevent
additional complications. It is through this vigilance that there would be a feeling of responsible use of stimulants and improved patient outcomes in advanced care nursing
models.
Slide 8: Common Side Effects
Insomnia was reported to require nursing intervention strategies
Gastrointestinal upset, nausea, and dizziness are commonly observed (Chiappini et al.,
2025)
Appetite suppression causes a nutritional imbalance in weight
Mood irritability requires continuous behavioral monitoring
Dry mouth and headaches persist during initiation
Nursing interventions include timing the education administration
The side effects associated with Evekeo are common and are due to the stimulant effect that it has
has, and will require proactive nursing interventions. Usage of medication towards the end of
The day causes insomnia, and hence, education on timing is needed. Gastrointestinal
Symptoms such as nausea and dizziness are also present, and they emerge at an early point in
The treatment, but they are usually alleviated by eating (Chiappini et al., 2025). Routine monitoring
of nutritional status and growth pattern is required in the pediatric patient, as the weight loss
It may be devastating due to the fact that the appetite may be suppressed. Mood changes can
occur, including irritability and restlessness, and affect normal functioning and require
emotional support. Dry mouth and headaches are some of the most frequent side effects that
are reported during the first phase of treatment. The most critical players in informing
patients on taking medicine, changing their diets, and hydrating themselves are nurses. These
Interventions increase adherence and comfort. The regular assessment assists in avoiding the
complication onset with time and encourages patient-centered and safe stimulant care.
Slide 9: Unique or Serious Side Effects
Peripheral vasculopathy, Raynaud phenomenon, concerning adverse
FDA black box warning abuse dependence
Cardiac arrhythmias require immediate medical intervention (Yow et al., 2024)
Psychotic symptoms, such as hallucinations, indicate dosage reevaluation
Growth suppression prolonged pediatric stimulant exposure
Emergency symptoms include syncope, chest pain
Evekeo is associated with serious risks, and these risks are to be observed and explained to
patients. Raynaud phenomenon is a specific comorbidity of stimulants, peripheral
vasculopathy, and is characterized by discoloration of the digits and pain of an ischemic
nature. The FDA black box warns of a great possibility of abuse and dependence, and it is
strongly prescribed. Arrhythmia and sudden cardiac events are cardiovascular complications
that demand immediate medical treatment (Yow et al., 2024). Hallucinations and paranoia are
examples of psychotic symptoms that should prompt a new assessment regarding therapeutic
care. Pediatrics Long-term pediatric drug use can inhibit growth, and height and weight
monitoring are essential. Such warning symptoms as syncope, chest pain, and extreme
behavioral changes require urgent treatment. Nurses should train patients and caregivers to be
aware of such symptoms and offer continuous monitoring so that they can be clinically
responded to early and ensure the safety of treatment.
Slide 10: Pricing and Insurance Coverage
Retail pricing varies geographically, pharmacy-dependent
Generic formulations significantly reduce treatment expenses
Insurance often requires prior authorization documentation
Formulary restrictions limit dosage quantity approvals
Nurses advocate submit clinical necessity documentation
Patient assistance improves medication affordability and access
Evekeo is available at different prices depending on geographical locations, pharmacies, and
dosage strength. Generic amphetamine sulfate is much more cost-effective in terms of
treatment costs, which are made affordable to many patients. Nonetheless, insurance companies often request prior approval, and that can slow down access. Restrictions on the
dosage and number of refills that may be made in the course of the prescriptions can also be
applied by the formula, and they require more clinical records. Nurses are usually in the central
positions to represent patients by providing supporting facts of medical necessity and aligning
with prescribers and insurance companies. Financial burden is relieved with the help of
patient assistance programs and discounted services, as well as better adherence to therapy.
Appreciating these factors of the economy enables nurses to promote fair access to care and
alleviate medical-related financial burden on patients. This is necessary to ensure continuity
of care and promote positive treatment outcomes.
Slide 11: Clinical Scenario
A student with ADHD is experiencing academic concentration impairment
Reports impulsivity, distractibility, and inefficient task completion
The extended release caused intolerable effects of insomnia
Evekeo immediate release selected targeted control
Expected outcomes improved academic performance
Nursing cardiovascular monitoring adherence education support
This case is of a 22-year-old university student with ADHD who claims he has a considerable
amount of difficulty concentrating during lectures and finishing assignments. This was
because of having a history of severe evening insomnia and fatigue after taking an extended-
A release stimulant, which had adverse effects on academic performance. Evekeo immediate
The release has been chosen because it was necessary to have precise control at the time of
scheduled studies. This will enable customized symptom control that is limited only to academically demanding times. It is expected that the results will be of improved quality
focus, decreased impulsivity, and better performance on tasks. The nursing roles involve
following cardiovascular parameters, enhancing compliance, and informing the patient about
The identification of adverse effects. Favorable counseling is concerned with sleep hygiene
and nutritional upkeep. This example shows the role of clinical reasoning in choosing
medications and the significance of making personalized decisions on therapy in advanced
nursing practice.
Slide 12: References
Chiappini, S., Gramuglia, P. D., Palagini, L., Miuli, A., Auriacombe, M., & Martinotti, G.
(2025). Management of Insomnia Associated with Chronic Stimulant Use: A
Systematic Review of Pharmacological and Non-Pharmacological Interventions.
Psychiatry International, 6(4), 121. https://doi.org/10.3390/psychiatryint6040121
Martin, D., & Le, J. K. (2023, July 31). Amphetamine. StatPearls – NCBI Bookshelf.
https://www.ncbi.nlm.nih.gov/books/NBK556103/
Patel, P., Marwaha, R., & Molla, M. (2025, April 6). Dextroamphetamine-Amphetamine.
StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK507808/
Simon, L. V., Torrico, T. J., & Keenaghan, M. (2024, March 2). Serotonin Syndrome.
StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK482377/
Yow, A. G., Rajasurya, V., Ahmed, I., & Sharma, S. (2024, March 16). Sudden cardiac
death. StatPearls – NCBI Bookshelf.
https://www.ncbi.nlm.nih.gov/books/NBK507854/
CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER.
Topic
amphetamine sulfate (Evekeo)
Type
PowerPoint presentation
Education level
Master’s
Citation style
APA 7th edition
Service
Writing
Add-ons
Plagiarism & AI report
Size
10 slides (2,750 words), double spacing
Sources
4 sources required
Subject
Nursing
Language
English (US)
Description
- Basic medication information: Why the medication is unique, dosing guidelines, significant interactions/ contraindications, typical side effects/ unique side effects
- Information about pricing/ insurance coverage
- Example clinical scenario of when it would be appropriate to use the medication
Use a minimum of two scholarly sources to gather information for the presentation. Make sure to create a reference page.
ADHD Assignment – Evaluation Criteria
| Criteria | Excellent | Proficient | Needs Improvement | Unsatisfactory | Pts |
|---|---|---|---|---|---|
| Topic ContentIncludes basic medication information:1. Unique features associated with the medication2. Dosing guidelines3. Major interactions/contraindications. Common side effects / unique side effects. Pricing/insurance information | 5 ptsMeets all requirements. | 4 ptsMeets 4 criteria. | 2 ptsMeets 2 criteria. | 0 pts | 5 pts |
| Clinical Scenario: Discuss an appropriate clinical scenario | 1 ptMeets all criteria. | — | 0.5 pts. Clinical scenario lacks detail and/or is inappropriate. | 0 pts | 1 pt |